uploads///

What Analysts Are Recommending for Trulieve Cannabis

By

Feb. 25 2019, Updated 12:00 p.m. ET

Analysts’ recommendation

Of the three analysts that follow Trulieve Cannabis (TRUL) (TCNNF), one analyst has given the stock a “strong buy” rating, while the other two analysts are favoring a “buy” rating. On average, analysts have given the stock a price target of 26 Canadian dollars, which represents an upside potential of 44.8% from its February 22 closing price of 17.96 Canadian dollars.

Article continues below advertisement

Peer comparisons

  • Of the seven analysts that cover Tilray (TLRY), three have given it “buys,” and four have given it “holds.” On average, analysts have given the stock a price target of $131.25, which represents a potential upside of 66% from its February 22 closing price of $79.07.
  • Of the 11 analysts that follow HEXO (HEXO), three analysts have given it a “strong buy” rating, and eight have given it “buy” ratings. On average, analysts have set a price target of 9.66 Canadian dollars on the stock, which represents a potential upside of 24.6% from its February 22 closing price of 7.75 Canadian dollars.
  • Of the ten analysts that follow Aphria (APHA), seven analysts are favoring a “buy,” while two analysts have given it a “hold” rating and one analyst has given it a “sell” rating. On average, analysts have given APHA a price target of 16.25 Canadian dollars, which represents a potential upside of 22.1% from its February 22 closing price of 13.31 Canadian dollars.

Valuation multiples

As of February 22, Trulieve was trading at a forward EV-to-sales multiple of 0.57x. On the same day, its peers Tilray, HEXO, and Aphria were trading at a forward EV-to-sales multiple 37.3x, 7.93x, and 4.88x, respectively.

Also, on the same day, Trulieve was trading at a forward EV-to-EBITDA multiple of 1.28x. Peers HEXO and Aphria were trading at a forward EV-to-EBITDA multiple of 36.8x and 40.8x, respectively.

Advertisement

More From Market Realist